Human endogenous retrovirus K (HML-2) RNA and protein expression is a marker for human embryonic and induced pluripotent stem cells by Fuchs, N.V. et al.
Fuchs et al. Retrovirology 2013, 10:115
http://www.retrovirology.com/content/10/1/115SHORT REPORT Open AccessHuman endogenous retrovirus K (HML-2) RNA
and protein expression is a marker for human
embryonic and induced pluripotent stem cells
Nina V Fuchs1,4*†, Sabine Loewer2,3†, George Q Daley2, Zsuzsanna Izsvák4, Johannes Löwer1* and Roswitha Löwer1Abstract
Background: Malignant human embryonal carcinoma cells (ECCs) rely on similar transcriptional networks as
non-malignant embryonic stem cells (ESCs) to control selfrenewal, maintain pluripotency, and inhibit differentiation.
Because re-activation of silenced HERV-K(HML-2) loci is a hallmark of ECCs, we asked if this HERV group was also
reactivated in ESCs and induced pluripotent stem cells (iPSCs).
Findings: Using RT-PCR and Western Blot, we demonstrate HERV-K(HML-2) RNA and protein expression in
undifferentiated human ESCs and iPSCs. Induction of differentiation by embryoid body formation resulted in
rapid silencing of HERV-K(HML-2) provirus expression. Sequencing analysis of a conserved region of the gag gene
showed that proviral expression in ESCs and iPSCs represents at least 11 of the 66 nearly full length HERV-K(HML-2) loci,
with slightly varying patterns in individual cell lines. These proviruses are human specific integrations and
harbor promoter competent long terminal repeats (LTR5hs subgroup). We observed high mRNA levels of the
NP9 and Gag encoding proviruses K101(22q11.21) in all and K10(5q33.3) in most of the ECC, ESC, and iPSC lines tested,
while K37(11q23.3) mRNA was detected only in ESCs and iPSCs. In addition, we detected expression of proviral mRNA
encoding the RNA export adaptor Rec in all cell lines studied. Proviral mRNA originating from the K108(7p22.1) locus,
which inter alia codes for functional Rec and Env proteins, was only reactivated in malignant ECC lines, not in benign
ESCs or iPSCs.
Conclusions: HERV-K(HML-2) RNA and protein expression is a marker for pluripotent human stem cells. Initiation of
differentiation results in rapid down-regulation. Further studies are needed to explore a putative functional role of
HERV-K(HML-2) RNA and proteins in pluripotent stem cells.
Keywords: Human embryonic stem cells, Induced pluripotent stem cells, Activation of human endogenous retrovirus K
proviruses, Embryoid body differentiation, Pluripotency markerFindings
Although no infectious HERV particles have been detected
to date, several proviruses of the evolutionary young
hominoid group HERV-K(HML-2) harbor open reading
frames for viral proteins, as well as promoter competent
long terminal repeats (LTRs) [1,2]. Two subgroups exist
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reproduction in any medium, provided the orprotein Rec, which mediates nuclear-cytoplasmic trans-
location of incompletely spliced RNA, thereby allowing
translation of viral proteins [3]. Type 1 proviruses harbor
a 292-bp deletion within the pol-env boundary, resulting
in loss of a functional open reading frame for Rec, but
gaining a functional open reading frame for the accessory
protein Np9 [4]. In vitro assays have shown that Rec and
Np9 interact with cellular proteins like the promyelocytic
leukemia zinc finger protein (PLZF), ligand of numb
protein X (LNX), testicular zinc-finger protein, androgen
receptor, and small glutamine-rich tetratricopeptide repeat
protein and might thus support cell transformation [5-9].
Although HERV-K(HML-2) proviruses may be transcribed
in somatic cells [10,11], up-regulated transcription andtd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 1 HERV-K(HML-2) expressed at RNA and protein level in ES/iPS cells. A) Prototypic HERV-K(HML-2) open reading frames B) Type 1
and 2 mRNA species, Δ denotes the 292 bp deletion in type 1 proviruses. 1) full length type 2, 1Δ) full length type 1, 2) env mRNA type 2, 2Δ) env
mRNA type 1, 3) 1.8 kb mRNA type 2 encoding rec [18], 3Δ) 1.5 kb mRNA type 1 encoding Np9 [4], 4) 1.5 kb mRNA derived from type 1 or type 2
[18]. PCR primers are indicated by arrows and arrowheads. Primers PrevENV, PrevREC, PrevNP9 overlap the immediate upstream splice site. C) RT-PCR of
HERV-K(HML-2) expression in ES cells (H1, H9, BG01), fibroblasts (MRC5, MSC, hFib2) and corresponding iPS cells using the primer pair K20 and K6. OCT4,
NANOG served as pluripotency, LMNA as differentiation markers, ACTB as internal control [19,20]. D) Western blot for HERV-K(HML-2) Gag, OCT4 and
ACTB in ES, iPS, fibroblast and EC cells.
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induction of an anti-HERV-K(HML-2) immune response
are predominantly associated with germ cell tumors,
embryonal carcinoma cell (ECC) lines, melanomas and
other cancers [12-17].
The phenotype and transcriptional profile of ECCs
resemble that of non-malignant pluripotent embryonic
stem cells (ESCs) and induced pluripotent stem cells
(iPSCs) in that they express key pluripotency factors
such as OCT4, NANOG and SOX2 and other markers
characteristic of pluripotent stem cells [reviewed in [21]].
In addition, ECCs rely on similar pathways to regulate
self-renewal and inhibition of differentiation [21], such as
autocrine FGF signalling and activation of downstreamsignalling cascades, especially the ERK/MEK pathway
[22,23]. These similarities prompted us to test whether
HERV-K(HML-2) RNA and protein expression, which
is a marker of ECCs, might also be reactivated in non-
malignant pluripotent stem cells.
HERV-K(HML-2) RNA and proteins are expressed in ESCs
and iPSCs
We analyzed the expression of HERV-K(HML-2) in three
ESC lines (H1, H9, BG01), three fibroblast lines (MRC5,
MSC, hFib2) and iPSC lines derived from these fibro-
blasts. All materials and methods are described in detail
in Additional file 1 “Materials and Methods”. To augment
the probability to detect HERV-K(HML-2) transcripts
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spliced viral RNA by RT-PCR. Full length and spliced
transcripts and the location of all primer pairs used are
depicted in Figure 1B. We verified expression of the
endogenous pluripotency genes OCT4 and NANOG and
absence of the differentiation marker gene LMNA in
pluripotent stem cells, ACTB specific amplicons served
as internal controls [19,20]. We did not detect any
HERV-K(HML-2) specific amplicons in any of the fibroblast
cell lines, which readily expressed the differentiation
marker LMNA. In contrast, all ESC and iPSC lines tested
showed expression of all three types of completely spliced
HERV-K(HML-2) transcripts, in addition to the pluripotency
markers OCT4 and NANOG (Figure 1C). The intensities
of the PCR amplicons varied between individual ESC/
iPSC lines, suggesting differential activation of proviruses
between lines.
The presence of spliced HERV-K(HML-2) type 2 tran-
scripts in all pluripotent stem cell lines tested prompted
us to investigate whether they encode functional Rec
protein and thus enable translation of HERV-K(HML-2)
Gag and Env proteins. Using a HERV-K(HML-2) Gag
specific monoclonal antibody in Western blot analysis,
we indeed detected low to moderate levels of this protein
in the H9 ESCs and the hFib2-iPS5 iPSC line, but not
in the parental fibroblasts hFib2. By contrast, the ECC
line GH showed high levels of Gag protein expression
(Figure 1D). To ensure the phenotypic similarity between
the malignant ECC line and the non-malignant ESC/iPSC
lines, we verified by RT-PCR that GH cells expressed the
pluripotency markers OCT4, NANOG, SOX2, STELLA
as well as the autocrine signaling factor FGF4 (data not
shown). The differences in HERV-K(HML-2) Gag protein
levels observed in H9 and hFib2-iPS5 correlated with
the differences in signal intensities of their rec specific
amplicons in RT-PCRs (Figure 1C, compare intensities of
amplicons 3), which is consistent with the idea that theFigure 2 HERV-K(HML-2) expression is immediately down-regulated d
HERV-K(HML-2) expression in hFib2- iPS5 cells using the primer pair K21 and
of provirus ERVK-17 (see Table 1) which contains a small deletion in the am
(see Additional file 1 “Materials and Methods”) B) Quantitative expression a
LMNA, and ACTB serve as control [19,20]. RNA levels are depicted relative tolevels of functional Rec protein determine the efficiency of
Gag protein translation.Differentiation induces silencing of HERV-K(HML-2)
proviruses
To determine whether HERV-K(HML-2) expression in
pluripotent stem cells changes during differentiation, we
induced embryoid body formation of hFib2-iPS5 cells. We
applied semi-qRT-PCR analysis using the primer pair K7/
K21 (see Figure 1B). Interestingly, the levels of HERV-K
(HML-2) RNA started to decrease from day 6 onwards
in hFib2-iPS5 cells, concomitant with a decrease of
NANOG and an increase of LMNA expression (Figure 2A).
To estimate the degree of the changes we quantified
the signal intensities of the RT-PCR bands visualized by
ethidium bromide gel analysis (Figure 2A) relative to
ACTB (see Additional file 1 “Materials and Methods”).
HERV-K(HML-2) expression levels dropped from 100%
on day 0 to roughly 50% on day 6, and to 20% on day
10. Similarly, NANOG expression levels decreased from
100% on day 0 to roughly 75% on day 6, and 55% on
day 10.
To verify this with a second method and cell line, we
performed real-time RT-PCR analysis using differentiating
H9 ESCs [19,20]. This analysis showed an even more
dramatic reduction of HERV-K(HML-2) RNA expression
during differentiation with significantly reduced transcrip-
tion already detectable on day 2 of embryoid body differ-
entiation (Figure 2B). Remarkably, the kinetics of HERV-K
(HML-2) downregulation is even faster than repression of
OCT4 and NANOG.
These slightly divergent results may simply reflect the
greater accuracy of real time PCR compared to semi-
quantitive PCR or may be rooted in the well-known subtle
differences in the expression profiles of pluripotent stem
cells especially those of ESC compared to iPSC lines [24].uring embryoid body differentiation. A) Semi-quantitative RT-PCR of
K7. The faint band at ≈570 bp presumably represents the rec mRNA
plified region. LMNA was amplified using an alternative primer
nalysis of HERV-K(HML-2) env, rec and Np9 transcripts in H9 cells. OCT4,
undifferentiated cells on day 0 (n=2, error bars +/−s.e.m).
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endogenous retrovirus group HERV-H [25] and expression
of non-LTR retrotransposons [26] are also associated with
human pluripotent stem cells indicate that a pluripotent
phenotype might be accompanied by a general relieve
of retroelement silencing. We therefore asked whether
re-activation of HERV-K(HML-2) proviruses is specific
for certain proviral elements or occurs in a stochastic
manner.
HERV-K(HML-2) proviruses are activated in ESC/iPSC/ECC
lines in varying patterns
We analyzed activation of HERV-K(HML-2) proviruses
in malignant and non-malignant pluripotent stem cells
using an established protocol [27] to amplify, clone,
and sequence a highly conserved part of the gag gene
(see Additional file 1 “Materials and Methods”). A proviral
sequence was scored as the genomic origin of the re-
spective clone when the two sequences exerted more than
98% identity (Additional file 2 “Alignments”, .msf filesTable 1 Relative cloning frequencies of HERV-K(HML-2) loci tr
ESC ESC ESC iPSC
Alias Type ORF BG01 H1 H9 MRC
iPS7
K101(22q11.21) 1 g/n 64 60 57 69
ERVK-24
K10(5q33.3) 1 g/prt/n - 26 7,3 8
ERVK-10
K109(6q14.1) 2 g/prt/e/r - 7 7,3 -
ERVK-9
K106(3q13.2) 1 g/n - - - -
ERVK-3
K37(11q23.3) 1 g/prt/n 36 - 14 15
ERVK-20
HKc10-B(10q24.2) 2 g/r - 7 7 -
ERVK-17
KI(3q21.2) 2 r - - - 8
ERVK-4
K115(8p23.1) 2 pol/e/r - - - -
ERVK-8
K41(12q14.1) 2 g/prt/e/r - - 7,3 -
ERVK-21
K108(7p22.1) 2 g/prt/e/r - - - -
ERVK-6
K102(1q22) 1 n - - - -
ERVK-7
Proviruses are designated by name and chromosomal locus, by type and putative o
the respective HERV-K(HML-2) loci are given as % (number of sequences assigned t
cDNA sample). 14 clones were generated and analyzed for BG01, 2102Ep, H9; 15 fo
19 for MSCiPS1 and NCCIT, 24 for GH. Open reading frames for Gag (g), Protease (pof these alignments are available as Additional files 3
“K101(22q11.21)”, 4 “K10(5q33.3)”, 5 “K106(3q13.2)”, 6
“K115(8p23.1)”, 7 “K37(11q23.3)”, 8 “K102(1q22)”, 9
“K108(7p22.1)”, 10 “HKc10-B(10q24.2)”, 11 “K41(12q14.1)”,
12 “K109(6q14.1)” and 13 “KI(3q21.2)”). Out of the 66
full-length or nearly full-length HERV-K(HML-2) proviruses
present in the human genome [1], a subset of 11 were
found to be expressed in patterns, which varied from
cell line to cell line (Table 1). More activated loci may be
detected using optimized primers [28], deep sequencing
techniques [29] as well as more cell lines. Notably, all
transcribed loci belong to the LTR5Hs subgroup of
HERV-K(HML-2) proviruses. Interestingly, phylogenetic
classifications have shown that all human-specific retroviral
integrations fall into this proviral subgroup [1]. Indeed,
ten of the expressed proviruses were human-specific,
while K37(11q23.3) may also be present in the genomes
of great apes. Five of the re-activated proviruses belonged
to type 1 and six to type 2 genotypes, respectively, but
their number and expression levels varied betweenanscribed in ESC, iPSC and ECC lines
iPSC iPSC iPSC iPSC iPSC ECC ECC ECC
MRC MSC MSC hFib2 hFib2 GH NCCIT 2102
iPS20 iPS1 iPS3 iPS4 iPS5 Ep
61 56 88 62 39 75 16 29
23 5,5 6 - 22 8,5 21 -
8 - - - - - - 42
- 5,5 - 8 11 - 5 -
8 22 - 15 16 - - -
- 11 - - 6 - - -
- - 6 - 6 - - -
- - - 15 - - - -
- - - - - - - -
- - - - - 16,5 11 29
- - - - - - 47 -
pen reading frames (ORF). For each cell line the relative cloning frequencies of
o the locus divided by the total number of sequences generated from the
r H1; 13 for MRCiPS7, MRCiPS20, hFib2iPS4; 17 for MSCiPS3; 18 for hFib2iPS5;
rt) Envelope (e), Rec (r) NP9 (n).
Fuchs et al. Retrovirology 2013, 10:115 Page 5 of 6
http://www.retrovirology.com/content/10/1/115individual ESC/iPSC and ECC cell lines. Such variations
in HERV-K(HML-2) proviral transcription profiles are
commonly observed in somatic malignant and non-
malignant tissues and cell lines [10,28] indicating a
somewhat stochastic re-activation mechanism which
may reflect varying chromatin dynamics [30]. By contrast,
we observed constant and efficient transcription of the
type 1 provirus K101(22q11.21) in all pluripotent stem cell
lines tested, suggesting a more directed re-activation.
K101(22q11.21), K37(11q23.3) and K10(5q33.3) encode gag
and protease genes and may account for the protein
expression detected, e.g. in the H9 and hFib2-iPS5 lines
(Figure 1D). Transcription of one or the other type 2 locus
was detected in the ESC/iPSC lines, but only at low level.
This is in contrast to the observed constant up-regulation
of K108(7p22.1) expression exclusively in the malignant
ECC lines. Notably, a recent survey of HERV-K(HML-2)
proviruses transcribed in melanomas in comparison to
melanocytes also demonstrated K108(7p22.1) derived
mRNA only in melanomas but not in the non-malignant
precursor cells [28].
Conclusion
The endogenous betaretrovirus group HERV-K(HML-2)
is unique in its potential to code for viral and accessory
proteins. We observed, in slightly varying patterns, re-
activation at the RNA and protein levels of certain human
specific, protein encoding HERV-K(HML-2) proviruses
with promoter competent LTR sequences in pluripotent
ESCs, iPSCs, and ECCs. The surprisingly constant activa-
tion of K101(22q11.21) across all cell lines tested may indi-
cate a particular function in or association with
pluripotency. We detected K108(7p22.1) only in the malig-
nant ECC lines. This corresponds to up-regulated K108
(7p22.1) transcription described in other germ cell tu-
mours, in brain tumours but not in normal brain [10]
as well as in malignant melanoma [28] but not in mela-
nocytes. HERV-K(HML-2) proviruses were rapidly si-
lenced upon embryoid body differentiation. Re-activation
of this HERV group thus represents another marker for
the undifferentiated state of pluripotent stem cells.
Active type 2 proviruses produce Rec protein, which
supports cell transformation in vitro and germ line carcin-
oma in situ in transgenic mice [7,31]. Type 1 proviruses
produce Np9 protein [4]. Both Rec and Np9 interact with
transcriptional regulators. For example, Rec and Np9 bind
the MYC repressor PLZF resulting in overexpression
of MYC [6] and Np9 can bind to LNX [8] which might
influence the activity of the NOTCH pathway. MYC
and NOTCH are often involved in carcinogenesis but
are also important players in the signalling networks
controlling self-renewal, pluripotency and differentiation
[32]. Since there are substantial differences between the
cell cycle regulation of murine and human pluripotentstem cells [21], it is intriguing to speculate that Rec and
Np9, which are not encoded by rodent ERVs, might play
positive roles in human ESC/iPSCs. The observation that
Rec and Np9 encoding HERV-K(HML-2) proviruses were
preferentially activated in pluripotent stem cells and that
their expression was simultaneously silenced upon differ-
entiation independent of their chromosomal localization is
in favour of such an idea.
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